Bechtold, 20121111 Bechtold S, Beyerlein A, Ripperger P, Roeb J, Dalla PR, Hafner R, et al. Total pubertal growth in patients with juvenile idiopathic arthritis treated with growth hormone: analysis of a single center. Growth Horm IGF Res. 2012;22:180-5.
(Deutschland) |
39 patients (systemic/polyarticular JIA) 24 controls |
(8-13) |
≅5 |
0.047 |
6.32 ± 1.96 |
GH had positive effects on height and pubertal development |
Bismuth E, 20102828 Bismuth EA, Chevenne DB, Czernichow PA, Simon DA. Moderate deterioration in glucose tolerance during high-dose growth hormone therapy in glucocorticoid-treated patients with juvenile idiopathic arthritis. Horm Res Paediatr. 2010;73:465-72.
(France) |
43 patients (systemic/polyarticular JIA) 15 controls |
(4-14) (4-8) |
3.9 ± 2.7 4.3 ± 2.9 |
0.065 |
3 |
GH combined with glucocorticoids was associated with a significant increase in fasting insulin level |
Bechtold, 20101212 Bechtold S, Ripperger P, Dalla PR, Roth J, Hafner R, Michels H, et al. Dynamics of body composition and bone in patients with juvenile idiopathic arthritis treated with growth hormone. J Clin Endocrinol Metab. 2010;95:178-85.
(Deutschland) |
12 patients (systemic/polyarticular JIA) |
(9-14) |
8.49 ± 2.9 |
- |
5.35 ± 0.7 |
Benefits in anthropometric levels, and fat levels stabilized |
Bechtold, 20071313 Bechtold S, Ripperger P, Dalla PR, Bonfig W, Hafneer R, Michels H. Growth hormone increases final height in patients with juvenile idiopathic arthritis: data from a randomized controlled study. J Clin Endocrinol Metab. 2007;92:3013-8.
(Deutschland) |
31 patients (systemic/polyarticular JIA) 18 controls |
(10-14) |
3,7 ± 1,2 |
0.047 |
8.4 |
Patients reached the height within the standard target set |
Simon, 20071414 Simon D, Prieur AM, Quartier P, Charles Ruiz J, Czernichow P. Early recombinant human growth hormone treatment in glucocorticoid-treated children with juvenile idiopathic arthritis: a 3-year randomized study. J Clin Endocrinol Metab. 2007;92:2567-73.
(France) |
30 patients (systemic/polyarticular JIA) |
(7-12) |
- |
0.065 |
3 |
Benefits in anthropometric levels Bone mineralization with no significant difference Increased blood glucose |
Bechtold, 20051515 Bechtold S, Ripperger P, Bonfig W, Pozza RD, Haefner R, Schwarz HP. Growth hormone changes bone geometry and body composition in patients with juvenile idiopathic arthritis requiring glucocorticoid treatment: a controlled study using peripheral quantitative computed tomography. J Clin Endocrinol Metab. 2005;90:3168-73.
(Deutschland) |
17 patients (systemic/polyarticular JIA) |
(12-17) |
8.2 ± 4.4 |
(0.036-0.047) |
4 |
GH had positive and significant effects on height and muscle mass |
Saha, 20041616 Saha MT, Haapasaari J, Hannula S, Sarna S, Lenko HL. Growth hormone is effective in the treatment of severe growth retardation in children with juvenile chronic arthritis. Double blind placebo-controlled followup study. J Rheumatol. 2004;31:1413-7.
(Finland) |
25 patients (12 polyarticular JIA, 10 oligoarticular JIA and 3 systemic JIA) |
(8-11) |
- |
0.033 |
0.5 (6 months) |
Patients with GH treatment grew faster versus control group |
Bechtold, 20041717 Bechtold S, Ripperger P, Bonfig W, Schmidt H, Bitterling H, Hafner R, et al. Bone mass development and bone metabolism in juvenile idiopathic arthritis. J Rheumatol. 2004;31:1407-12.
(Deutschland) |
11 patients (systemic/polyarticular JIA) |
(9-11) |
3.7 ± 1.4 |
0.047 |
4 |
Significant increase in height, and improvement in bone remodeling |
Bechtold, 20031818 Bechtold S, Ripperger P, Häfner R, Said E, Schwarz HP. Growth hormone improves height in patients with juvenile idiopathic arthritis: 4-year data of a controlled study. J Pediatr. 2003;143:512-9.
(Deutschland) |
38 patients (systemic/polyarticular JIA) |
(5.5-13.8) |
≅3.8 |
(0.028-0.047) |
4 |
Significant increase in final height |
Simon, 20031919 Simon D, Lucidarme N, Prieur AM, Ruiz JC, Czernichow P. Effects on growth and body composition of growth hormone treatment in children with juvenile idiopathic arthritis requiring steroid therapy. J Rheumatol. 2003;30:2492-9.
(France) |
30 patients (systemic/polyarticular JIA) |
(6.8-13.0) |
8.2 (4.5-15.6) |
0.065 |
3 |
Improvement in growth rate Increases in lean body mass and bone mineral density Glucose intolerance observed in 6 patients Increase of glycosylated hemoglobin |
Simon, 200155 Simon D, Lucidarme N, Prieur AM, Ruiz JC. Czernichow linear growth in children suffering from juvenile idiopathic arthritis requiring steroid therapy: natural history and effects of growth hormone treatment on linear growth. J Pediatr Endocrinol Metab. 2001;6:1483-6.
(France) |
14 patients (systemic/polyarticular JIA) |
≅9.7 |
≅3 |
0.065 |
1 |
Improved growth rate and prevention of metabolic complications |
Al-Mutair, 20002020 Al-Mutair A, Bahabri S, Al-Mayouf S, Al-Ashwal A. Efficacy of recombinant human growth hormone in children with juvenile rheumatoid arthritis and growth failure. J Pediatr Endocrinol Metab. 2000;13:899-905.
(Saudi Arabia) |
10 patients (systemic/polyarticular JIA) |
(6-15) |
- |
0.027 |
1 and 3 |
Improved growth in the final height One patient developed deformities in both knees |
Touati, 20002121 Touati G, Ruiz JC, Porquet D, Kindermans C, Prieur AM, Czernichow P. Effects on bone metabolism of one year recombinant human growth hormone administration to children with juvenile chronic arthritis undergoing chronic steroid therapy. J Rheumatol. 2000;27:1287-93.
(France) |
14 patients (systemic/polyarticular JIA) |
(6-14) |
≅3 |
0.066 |
1 |
Significant increases in bone resorption markers Plasma level of osteocalcin was the best variable predictive of growth |
Rooney, 20002222 Rooney M, Davies UM, Reeve J, Preece M, Ansell BM, Woo PM. Bone mineral content and bone mineral metabolism: changes after growth hormone treatment in juvenile chronic arthritis. J Rheumatol. 2000;27:1073-81.
(England) |
20 patients (systemic/polyarticular JIA) |
7.6 |
- |
- |
1 |
Improvement of bone metabolism and height |
Simon, 20002323 Simon D, Prieur A, Czernichow P. Treatment of juvenile rheumatoid arthritis with growth hormone. Horm Res. 2000;53:82-6.
(France) |
14 patients (systemic/polyarticular JIA) |
≅9 |
- |
0.06 |
2 |
Increases in growth rate and lean mass Increase in bone mineral density |
Simon, 19992424 Simon D, Touati G, Prieur AM, Ruiz JC, Czernichow P. Growth hormone treatment of short stature and metabolic dysfunction in juvenile chronic arthritis. Acta Paediatr Suppl. 1999;88:100-5.
(France) |
14 patients (systemic/polyarticular JIA) |
(9-12) |
3 (9 months to ≅8 years) |
0.067 |
1 |
Improvement in growth rate Decrease in glucose tolerance and increase in glycosylated hemoglobin levels |
Touati, 19982525 Touati G, Prieur AM, Ruiz JC, Noel M, Czernichow P. Beneficial effects of one-year growth hormone administration to children with juvenile chronic arthritis on chronic steroid therapy. I. Effects on growth velocity and body composition. J Clin Endocrinol Metab. 1998;83:403-9.
(France) |
14 patients (systemic/polyarticular JIA) |
≅9 |
- |
0.066 |
1-2 |
Increase in growth Increase in lean mass and decrease in fat mass Increase of glucose tolerance and increase in glycosylated hemoglobin |